Short Interest in Hypera S.A. (OTCMKTS:HYPMY) Declines By 99.1%

Hypera S.A. (OTCMKTS:HYPMY) saw a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 100 shares, a decline of 99.1% from the February 28th total of 11,300 shares. Based on an average daily trading volume, of 15,800 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the shares of the company are sold short.

Hypera Stock Up 4.8 %

HYPMY opened at $3.51 on Thursday. Hypera has a 1-year low of $2.64 and a 1-year high of $6.83. The business has a 50 day moving average of $3.30 and a 200-day moving average of $3.70. The stock has a market capitalization of $2.22 billion, a price-to-earnings ratio of 8.78 and a beta of 0.99. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.68.

Hypera (OTCMKTS:HYPMY) last posted its quarterly earnings data on Thursday, March 20th. The company reported $0.02 earnings per share (EPS) for the quarter. Hypera had a net margin of 20.04% and a return on equity of 13.18%. The company had revenue of $258.56 million for the quarter.

About Hypera

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.